Low morbidity following 9,000-rad intracavitary endocurietherapy (ECT) using the Kumar Cervical Applicator and external-beam radiotherapy (EXRT) in the management of carcinoma of the uterine cervix.
The Kumar Cervical Applicator minimizes patient discomfort and improves patient mobility while reducing the tendency of the applicator to rotate during the 40 to 50 hours of uterine intracavitary endocurietherapy. Patients with previously untreated invasive carcinoma of the uterine cervix, F.I.G.O. stages IB-IVA, were treated with two Kumar intracavitary endocurietherapy (ECT) applications of 2,500 rad each to point "A," and 4,000 rad external-beam radiotherapy (EXRT) to midplane, for a total dose of 9,000 rad. The major complication rate was 2.7%, and the local control rate was 85% (22/26 patients) for stage I and II, and 91% (10/11 patients) for stage III and IVA.
D001918:Brachytherapy / Q000295:instrumentation* / Q000379:methods; D002277:Carcinoma / Q000532:radiotherapy*; D002588:Cesium Radioisotopes / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy*
D002588:Cesium Radioisotopes